Autosomal-Dominant Charcot-Marie-Tooth Disease Type 2 Due to TFG Mutation

Autosomal-dominant Charcot-Marie-Tooth disease type 2 due to TFG mutation is a rare, inherited nerve disease that affects the axons (the “wires”) of peripheral nerves. It runs in families in an autosomal-dominant way, which means a change (mutation) in one copy of the TFG gene is enough to cause illness. People usually notice problems in adulthood. The first signs are often slowly progressive weakness and thinning (atrophy) of muscles in the feet and lower legs, less brisk ankle reflexes, and mild numbness or tingling in the feet. Walking can become difficult because the ankles are weak and the toes may “drop.” Because this is a CMT type 2 (axonal) form, nerve conduction studies typically show reduced amplitudes (weaker signals) rather than very slow speed. Research has shown that TFG mutations can disturb how proteins are handled and trafficked inside nerve cells, leading to axon degeneration over time. PMC+3Orpha+3NCBI+3

AD-CMT2-TFG is a rare, inherited nerve disease where a change (mutation) in the TFG gene damages the long “wires” (axons) of the peripheral nerves. These nerves carry signals to move muscles and feel touch. Because it is autosomal dominant, a person with one changed copy of TFG can develop the disease and can pass it to children. Most people notice slow, steady weakness in the feet and legs (and later hands), high arches or hammertoes, and reduced reflexes. Electrophysiology usually shows an axonal pattern (reduced amplitudes with near-normal speeds), and genetic testing can confirm a TFG mutation. There is no cure yet, but symptoms can be managed with rehabilitation, braces, and sometimes surgery. Mayo Clinic+3Orpha+3NCBI+3

Why TFG matters. The TFG protein helps the cell’s shipping system (endoplasmic reticulum to Golgi) and axonal health. Several families with dominant axonal CMT (CMT2) carry pathogenic TFG changes. Lab and animal models suggest TFG haploinsufficiency (too little working TFG) leads to progressive neurite/axon degeneration—explaining the typical distal weakness and sensory loss. PubMed+2PMC+2

TFG-related CMT2 can overlap with a phenotype called hereditary motor and sensory neuropathy with proximal predominance (HMSN-P), where weakness is noticeable in muscles closer to the trunk (thighs, hips, shoulders) in addition to the usual distal involvement. Families have been reported in Japan, Korea, and elsewhere, confirming TFG as a disease-causing gene in this spectrum. Cell+1

---

Another names

• CMT2 due to TFG mutation

• Axonal Charcot-Marie-Tooth disease due to TFG

• Hereditary motor and sensory neuropathy (HMSN) type 2—TFG-related

• HMSN-P (proximal-predominant) due to TFG (phenotypic overlap reported) Orpha+1

---

Types

1. Classic distal-predominant CMT2 (TFG-related): adult onset, slowly progressive foot and lower-leg weakness, reduced ankle reflexes, mild distal sensory loss. Orpha

2. Proximal-predominant (HMSN-P) spectrum: prominent weakness in thigh/hip or shoulder muscles early, followed by distal sensory problems; autosomal-dominant inheritance confirmed with TFG variants. Cell+1

3. Variable severity subtypes: some families show faster progression or more sensory fiber involvement than others, even with TFG mutations. JAMA Network

4. Age-at-onset variation: most often adult, but range can vary among families with different TFG variants. Orpha

---

Causes

Important note: the primary cause is a pathogenic mutation in the TFG gene. Items below describe how that mutation harms nerves (pathways), typical genetic mechanisms, or recognized worsening factors. They are not separate non-genetic causes of this specific disease.

1. Pathogenic TFG gene variant (autosomal-dominant): a single harmful change in TFG is sufficient to cause axonal neuropathy in affected families. Orpha+1

2. Loss of normal TFG function (haploinsufficiency): some mutations reduce the amount of working TFG protein, which contributes to progressive neurite/axon degeneration. PubMed+1

3. Impaired ER-to-Golgi protein trafficking: TFG helps move newly made proteins; when this is disrupted, neurons accumulate stress and degenerate. PubMed

4. Endoplasmic reticulum (ER) stress and protein quality-control failure: faulty handling of proteins can trigger stress responses that damage long axons. OUP Academic

5. Disrupted axonal maintenance: long peripheral axons need steady supply of proteins and lipids; TFG defects disturb this supply chain, weakening axons. OUP Academic

6. Cytoskeletal and transport imbalance: secondary effects on axonal transport can starve nerve endings of needed materials, worsening axon loss. OUP Academic

7. Neuromuscular junction (NMJ) degeneration: experimental models suggest TFG loss in motor neurons is enough to cause NMJ breakdown and muscle atrophy. Nature

8. Dominant-negative effects (some variants): certain missense changes may interfere with normal TFG protein complexes, amplifying dysfunction. OUP Academic

9. Age-related vulnerability of long axons: longer axons are more sensitive to trafficking stress over decades, helping explain adult onset. NCBI

10. Genetic background (modifiers): other common variants in nerve-maintenance genes might modify severity within families (inferred across CMT2). NCBI

11. Metabolic stress (e.g., poorly controlled diabetes) as a worsening factor: not causal for TFG-CMT2, but can add extra axon stress and symptoms. NCBI

12. Nutritional deficiencies (e.g., severe B12 deficiency) as a worsening factor: can layer additional neuropathy onto the genetic condition. NCBI

13. Toxins/chemotherapy (e.g., vinca alkaloids) as worsening factors: may provoke extra nerve injury in people with inherited neuropathies. NCBI

14. Thyroid dysfunction as a worsening factor: untreated hypo- or hyper-thyroidism may aggravate neuropathic symptoms. NCBI

15. Alcohol overuse as a worsening factor: alcohol-induced neuropathy can add to baseline deficits. NCBI

16. Mechanical foot stress and ankle instability: muscle imbalance can worsen deformities and falls, accelerating disability. NCBI

17. Deconditioning: inactivity reduces muscle strength around weak joints, worsening overall function. NCBI

18. Infections with prolonged bed rest: temporary deconditioning can unmask weakness. NCBI

19. Sleep problems/pain-related fatigue: pain, cramps, and poor sleep lower daytime strength and balance. NCBI

20. Psychosocial stress: stress can amplify perception of pain and fatigue, further limiting activity. NCBI

---

Symptoms

1. Foot and ankle weakness: trouble climbing stairs or standing on toes/heels; common first sign. Orpha

2. Foot drop and tripping: toes catch the ground, causing stumbles. Orpha

3. Lower-leg muscle wasting: calves become thinner over time. Orpha

4. Reduced ankle reflexes: ankle jerks are faint or absent on exam. Orpha

5. Mild numbness or tingling in feet: “stocking” pattern sensory loss. Orpha

6. Gait difficulty: walking becomes slow or unsteady, especially on uneven ground. Orpha

7. Leg cramps or fasciculations (muscle twitching): may be an early clue and are described in proximal-predominant cases. JAMA Network

8. Hand weakness later on: fine motor tasks (buttons, keys) become harder as disease progresses. NCBI

9. Tremor (variable): reported more often in some families with TFG variants. JAMA Network

10. Balance problems and falls: numbness and weakness together affect stability. NCBI

11. Neuropathic pain (burning/aching): not universal, but can occur. NCBI

12. Pes cavus (high-arched foot) or hammertoes: from long-term muscle imbalance. NCBI

13. Proximal thigh or shoulder weakness (subset): characteristic of HMSN-P overlap. Cell

14. Fatigue with walking or standing: muscles tire quickly because they’re weak. NCBI

15. Cold sensitivity in feet: impaired small-fiber function can make feet feel cold or uncomfortable. NCBI

---

Diagnostic tests

A) Physical examination (bedside)

1. Neurologic strength testing (MRC grading): documents weakness pattern (ankle dorsiflexion/plantarflexion first; proximal muscles if HMSN-P). Orpha+1

2. Reflex testing: ankle reflexes reduced or absent; knees may be reduced later. Helps distinguish neuropathy from muscle disease. Orpha

3. Sensory testing: light touch, pin, vibration in feet show mild distal loss; maps severity over time. Orpha

4. Gait assessment and foot posture: looks for foot drop, steppage gait, pes cavus, or hammertoes. NCBI

5. Functional tests (toe/heel walking, chair rise): simple measures that reflect daily-life limitations and risk of falls. NCBI

B) Manual/bedside maneuvers and scales

6. 10-meter walk or timed up-and-go: quick speed/balance measures to track progression. NCBI

7. Romberg test: standing with eyes closed checks sensory ataxia from distal sensory loss. NCBI

8. CMT Examination Score (CMTES/CMTNS where available): standardized scales to quantify impairment/severity in CMT. NCBI

9. Hand function tasks (peg test, grip): document fine-motor impact if hands are involved. NCBI

10. Balance screen (single-leg stance): simple indicator of fall risk in neuropathy. NCBI

C) Laboratory and pathological tests

11. Targeted genetic testing for TFG: confirms the diagnosis when clinical and electrodiagnostic features suggest CMT2/HMSN-P. (Panels or exome may be used.) PubMed+1

12. Comprehensive CMT gene panel/exome: helpful if the suspected TFG variant is unknown; identifies many CMT subtypes. arupconsult.com

13. Basic blood tests (B12, glucose, thyroid): not to diagnose TFG-CMT2, but to rule out other treatable neuropathies that can worsen symptoms. NCBI

14. Creatine kinase (CK): usually normal or mildly elevated; helps exclude primary muscle disease. NCBI

15. Nerve biopsy (rarely needed): axonal loss without marked demyelination supports CMT2 if used in unclear cases; genetics preferred today. NCBI

D) Electrodiagnostic studies

16. Nerve conduction studies (NCS): show reduced compound muscle action potential amplitudes with relatively preserved speeds—pattern typical of axonal neuropathy in CMT2. NCBI

17. Electromyography (EMG): reveals chronic denervation and reinnervation (neurogenic changes) consistent with length-dependent axon loss. NCBI

18. Sensory nerve action potentials (SNAPs): may be reduced or absent in the sural nerve, sometimes early in certain TFG-related families. JAMA Network

E) Imaging and other tools

19. Muscle MRI of legs (and thighs if proximal pattern): shows fat replacement patterns that track chronic denervation and help phenotype (distal vs proximal). NCBI

20. Nerve ultrasound (or MRI neurography in select centers): can assess nerve size and structure; mostly adjunctive in CMT2. NCBI

Non-pharmacological treatments (therapies & others)

(Each item: brief explanation, purpose, mechanism—plain English)

1. Individualized physiotherapy program. A structured plan builds strength in remaining muscle units and maintains joint range. Goal: slower decline in function and safer walking. Mechanism: progressive resistance and task-specific practice improve motor unit recruitment without causing “overwork” weakness in CMT. PubMed+1

2. Progressive resistance training (PRT). Carefully dosed strengthening (e.g., dorsiflexors, plantarflexors, intrinsic hand muscles) preserves strength in children and adults with CMT. Purpose: maintain force for gait and grip. Mechanism: muscle hypertrophy/neuromuscular adaptation; trials show preserved dorsiflexion strength with targeted PRT. ScienceDirect

3. Aerobic/endurance training. Low-impact cycling or treadmill walking boosts stamina and reduces fatigue. Purpose: improve activity tolerance. Mechanism: cardiovascular conditioning with close monitoring (no evidence of harmful “overwork” in supervised programs). PubMed

4. Balance and proprioception exercises. Wobble board, tandem stance, and dynamic balance drills reduce falls. Purpose: better joint position sense and ankle stability. Mechanism: repeated sensory-motor challenges retrain central balance strategies. PubMed

5. Stretching and contracture prevention. Daily calf, hamstring, and plantar fascia stretching maintains range and reduces cramps. Purpose: preserve gait mechanics. Mechanism: viscoelastic creep and neuromodulation of muscle spindles. PubMed

6. Ankle-foot orthoses (AFOs). Carbon-fiber or hinged AFOs correct foot drop and prevent tripping. Purpose: safer, more energy-efficient walking. Mechanism: external support substitutes for weak dorsiflexors and controls ankle motion. PMC

7. Custom foot orthotics and shoe adaptations. Lateral posting, rocker soles, and extra-depth shoes redistribute pressure and improve push-off in cavovarus or flatfeet. Purpose: pain relief and stability. Mechanism: alters ground reaction forces and lever arms. PMC

8. Hand therapy & adaptive devices. Occupational therapy trains fine-motor tasks and introduces aids (built-up grips, button hooks). Purpose: independence in ADLs. Mechanism: task-specific practice and ergonomic compensation. NCBI

9. Fall-prevention home program. Lighting, removing cords/rugs, bathroom bars, and railings. Purpose: reduce injury risk. Mechanism: environmental modification lowers hazard exposure. Mayo Clinic

10. Energy conservation & pacing. Spreading tasks and using mobility aids as needed. Purpose: limit fatigue and maintain participation. Mechanism: workload management. NCBI

11. Pain self-management education. Heat/ice, relaxation, and sleep hygiene to complement meds when needed. Purpose: reduce neuropathic pain interference. Mechanism: modulation of pain perception and muscle tone. Mayo Clinic

12. Treadmill training with body-weight support (as indicated). Purpose: safe gait practice and endurance. Mechanism: repetitive stepping improves central pattern generation and ankle strategy. PubMed

13. Community-based exercise programs. Supervised group sessions improve adherence and mood. Purpose: long-term maintenance. Mechanism: social support and routine. PubMed

14. Orthopedic surgical consultation (timely). When deformities are rigid/painful, surgery improves alignment and function. Purpose: correct cavovarus, hammertoes, and instability. Mechanism: tendon transfers, osteotomies, or fusions restore plantigrade foot. PMC+1

15. Skin and foot-care education. Daily checks, moisture balance, nail care to prevent ulcers/infections. Purpose: reduce complications. Mechanism: early detection + offloading. Mayo Clinic

16. Ergonomics for repetitive tasks. Avoid prolonged pressure at nerve entrapment sites; alternate positions. Purpose: prevent pressure palsy in vulnerable axons. Mechanism: reduces mechanical stress on nerves. NCBI

17. Bracing for hands/wrists if needed. Night splints or functional braces to reduce strain and improve grip. Purpose: pain control and function. Mechanism: stabilizes joints and tendons. NCBI

18. Psychological support and counseling. Coping strategies for a chronic condition. Purpose: improve quality of life and adherence. Mechanism: CBT and supportive therapy reduce distress and pain amplification. Mayo Clinic

19. Genetic counseling. Discuss inheritance, testing options, and family planning. Purpose: informed decisions. Mechanism: clarifies 50% transmission risk in autosomal dominant TFG-CMT2. nhs.uk

20. Participation in clinical trials. Access to investigational therapies and natural history studies. Purpose: contribute to future treatments. Mechanism: structured monitoring; currently no disease-modifying therapy exists for CMT. PMC+1

---

Drug treatments

Important safety note: No drug is FDA-approved for CMT itself. The medicines below are used to treat symptoms (e.g., neuropathic pain, cramps, spasticity) and their FDA labels come from accessdata.fda.gov. Use in CMT is typically off-label; discuss with your clinician.

1. Duloxetine (Cymbalta). Purpose: neuropathic pain control. Class: SNRI. Usual dose: 60 mg once daily for DPNP; higher doses don’t add benefit but raise side-effects. Mechanism: boosts serotonin/norepinephrine in descending pain pathways. Common side-effects: nausea, somnolence, dry mouth; rare: liver injury. Note: some 2024 lots recalled for impurities—check your specific product. FDA Access Data+2FDA Access Data+2

2. Pregabalin (Lyrica). Purpose: neuropathic pain. Class: alpha-2-delta calcium-channel ligand. Dose: start 150 mg/day; titrate 300–450 mg/day (varies by indication). Mechanism: reduces excitatory neurotransmitter release. Side-effects: dizziness, edema, weight gain. FDA Access Data+1

3. Gabapentin (Neurontin). Purpose: neuropathic pain. Class: alpha-2-delta ligand. Typical range: 900–3600 mg/day in divided doses (per label for PHN; dosing individualized). Mechanism: modulates calcium channels and neuronal hyperexcitability. Side-effects: somnolence, dizziness. FDA Access Data+1

4. Capsaicin 8% patch (Qutenza). Purpose: localized neuropathic pain (e.g., feet). Dose: in-clinic 8% patch for 30–60 min at intervals. Mechanism: TRPV1 agonist causing defunctionalization of nociceptors. Side-effects: application-site pain/erythema; protect eyes/mucosa. FDA Access Data+1

5. Lidocaine 5% patch (Lidoderm/ZTlido 1.8%). Purpose: focal neuropathic pain. Dose: up to 12 hours on/12 off (per product). Mechanism: sodium-channel blockade in peripheral nerves. Side-effects: local erythema; rare systemic toxicity with overuse. FDA Access Data+2FDA Access Data+2

6. Tramadol / Tramadol ER. Purpose: second-line analgesic for moderate pain when others fail. Class: weak µ-opioid + SNRI properties. Dose: individualized; ER has specific titration. Risks: dependence, serotonin syndrome with SSRIs/SNRIs, lowers seizure threshold. FDA Access Data+1

7. Naproxen (various; Naprelan). Purpose: musculoskeletal pain from overuse or orthopedic issues; not for neuropathic pain itself. Class: NSAID. Dose: per product. Risks: GI bleeding, CV events—boxed warnings. FDA Access Data+1

8. Celecoxib (Celebrex). Purpose: analgesia with potentially less GI risk vs. non-selective NSAIDs; consider CV risk. Class: COX-2 inhibitor. Dose: per label. Risks: CV and GI warnings remain. FDA Access Data+1

9. Baclofen (Lyvispah/Fleqsuvy). Purpose: treat bothersome cramps/spasticity patterns some patients report. Class: GABA-B agonist muscle relaxant. Dose: start low and titrate; sedation common. FDA Access Data+1

10. Tizanidine (Zanaflex). Purpose: episodic relief of spasticity-like symptoms. Class: central α2-agonist. Dose: 2 mg initially; repeat every 6–8 h as needed (max three doses/day). Risks: hypotension, sedation; liver monitoring. FDA Access Data+1

11. OnabotulinumtoxinA (Botox). Purpose: focal muscle overactivity or painful dystonia patterns impacting function (select cases). Mechanism: blocks acetylcholine release at neuromuscular junction. Risks: localized weakness; black-box for spread of toxin effect. FDA Access Data

12. Amitriptyline. Purpose: off-label neuropathic pain and sleep benefit. Class: tricyclic antidepressant. Dose: often 10–25 mg nightly, titrate. Risks: anticholinergic effects, QT prolongation; avoid in glaucoma/urinary retention. FDA Access Data

13. Nortriptyline (Pamelor). Purpose: similar to amitriptyline with potentially better tolerability. Dose: low-dose at night, titrate. Risks: anticholinergic and cardiac precautions. FDA Access Data+1

14. Carbamazepine (Tegretol). Purpose: paroxysmal neuralgic pain (e.g., trigeminal neuralgia); limited role in CMT neuropathic pain broadly. Risks: hyponatremia, rash (HLA-B*1502 in certain ancestries), drug interactions. FDA Access Data

15. Oxcarbazepine (Trileptal). Purpose: alternate sodium-channel modulator for neuralgic pain patterns (off-label). Risks: hyponatremia, dizziness. FDA Access Data+1

16. Topical diclofenac gel (Voltaren). Purpose: focal joint/soft-tissue pain from deformity/overuse. Mechanism: local COX inhibition with lower systemic exposure. Risks: local irritation; avoid on broken skin. FDA Access Data+1

17. Venlafaxine XR (Effexor XR). Purpose: alternative SNRI for neuropathic pain in some patients. Risks: BP elevation, withdrawal if stopped abruptly. FDA Access Data

18. Lidocaine/prilocaine cream (EMLA) or lidocaine/tetracaine (Pliaglis). Purpose: pre-activity desensitization for focal allodynia (short-term). Risks: methemoglobinemia in infants; follow label use. FDA Access Data+1

19. Topical lidocaine system 1.8% (ZTLido). Purpose: like Lidoderm with different delivery; adheres well to mobile skin. Risks: same class cautions. FDA Access Data

20. Short-term acetaminophen (paracetamol). Purpose: add-on for musculoskeletal pain load when NSAIDs are unsuitable; monitor total daily dose. (While its label is not hosted as a single monograph like Rx products, it’s widely used per OTC labeling; clinicians individualize.) Mayo Clinic

Avoid known neurotoxic drugs when possible. Vincristine and taxanes have stronger associations with nerve injury and can worsen CMT—make sure any oncology/other specialist checks CMT drug-safety lists before prescribing. CMT Research Foundation+1

---

Dietary molecular supplements

(Evidence mainly from diabetic or mixed peripheral neuropathies; no supplement has proven disease-modifying benefit in CMT2-TFG. Always discuss interactions and doses with your clinician.)

1. Alpha-lipoic acid (ALA). 300–600 mg/day. Function: antioxidant that may reduce neuropathic pain and oxidative stress. Mechanism: improves mitochondrial redox status; RCTs in diabetic neuropathy show symptom improvements in the short term. PubMed+1

2. Acetyl-L-carnitine (ALC). 1000–2000 mg/day divided. Function: supports mitochondrial fatty-acid transport; meta-analyses suggest moderate pain reduction in peripheral neuropathic pain. PLOS+1

3. Coenzyme Q10. 100–200 mg/day. Function: electron-transport cofactor; small RCTs in diabetic neuropathy show pain improvement; a pilot in CMT has been explored. Mechanism: improves mitochondrial efficiency and lowers cytokines. ClinicalTrials.gov+3PubMed+3PubMed+3

4. Omega-3 fatty acids (EPA/DHA). ~1–2 g/day combined. Function: anti-inflammatory membrane effects; may aid neuropathic pain adjunctively. Mechanism: resolvins/protectins modulate nociception. (General neuropathy rationale; discuss with physician.) Mayo Clinic

5. Vitamin D (for deficiency). Dose per level (often 1000–2000 IU/day maintenance). Function: supports neuromuscular health; correct deficiency to help pain/fall risk. Mechanism: receptor-mediated effects on muscle/nerve. Mayo Clinic

6. B-complex with controlled B6. Keep B6 within RDA (excess B6 can cause neuropathy). Function: coenzymes in nerve metabolism. Mechanism: supports methylation/axon health; avoid megadoses. Mayo Clinic

7. Magnesium (as tolerated). 200–400 mg elemental/day. Function: muscle relaxation and cramp reduction. Mechanism: NMDA modulation; smooth muscle effects. Mayo Clinic

8. Curcumin (standardized). ~500–1000 mg/day. Function: anti-inflammatory adjunct; mechanistic support in neuropathic models. Mechanism: NF-κB inhibition. (Adjunctive; clinical data limited.) Mayo Clinic

9. N-acetylcysteine (NAC). 600–1200 mg/day. Function: glutathione precursor; antioxidant support. Mechanism: reduces oxidative nerve stress. (Adjunctive; clinician-guided.) Mayo Clinic

10. Resveratrol. 100–300 mg/day. Function: antioxidant/mitochondrial signaling via SIRT1; preclinical neuropathy support. (Limited clinical data.) Mayo Clinic

---

Immunity-booster / regenerative / stem-cell” drugs

At this time, there are no FDA-approved “immunity booster,” regenerative, or stem-cell drugs for Charcot-Marie-Tooth disease (including TFG-related CMT2). Using such products for CMT would be unapproved and not supported by FDA-labeled indications. The responsible approach is to avoid listing unproven agents as if they treat CMT and instead consider participation in well-designed clinical trials or use supportive therapies above. PMC+1

---

Surgeries

1. Tendon transfers (e.g., posterior tibial to dorsum). Why: correct foot drop and balance evertor/invertor forces. Helps active dorsiflexion during swing phase. PMC

2. Calcaneal osteotomy (lateralizing) ± midfoot osteotomies. Why: correct cavovarus alignment and redistribute load to achieve a plantigrade foot. PMC

3. Plantar fascia release. Why: reduce rigid high-arch tension contributing to cavus deformity and metatarsalgia. PMC

4. Toe procedures (e.g., IP fusion for hammertoes). Why: relieve pain, improve shoe wear, reduce callus/ulcer risk. PMC

5. Arthrodesis (triple or selective fusions) for rigid deformity. Why: salvage stability and pain relief when joints are stiff/arthritic. CU School of Medicine

---

Prevention tips

1. Regular exercise with supervision to maintain strength and balance—evidence supports exercise benefit in CMT. PubMed

2. Footwear and orthoses to prevent trips/ulcers. cmtausa.org

3. Home fall-proofing (lighting, grab bars). Mayo Clinic

4. Avoid neurotoxic drugs (e.g., vincristine, taxanes) when alternatives exist; if unavoidable, monitor closely. CMT Research Foundation+1

5. Skin checks and podiatry for pressure spots. Mayo Clinic

6. Energy and task pacing to limit fatigue-related falls. NCBI

7. Vaccinations & illness prevention to avoid deconditioning setbacks. Mayo Clinic

8. Weight management & joint protection to reduce load on unstable ankles/feet. Mayo Clinic

9. Ergonomics to avoid prolonged compression at entrapment sites. NCBI

10. Genetic counseling for family planning and cascade testing. nhs.uk

---

When to see a doctor

Contact your neurologist/rehabilitation team if you notice new foot drop, frequent falls, painful skin sores, sudden worsening weakness or numbness, severe cramps not relieved by simple measures, new hand weakness interfering with daily tasks, unexplained weight loss, medication side-effects (excessive sleepiness, swelling, mood changes), or if a new doctor wants to prescribe a known neurotoxin. These changes may need urgent evaluation, bracing adjustments, medication review, or imaging/electrodiagnostics. Mayo Clinic+1

---

What to eat and what to avoid

Eat: balanced meals with lean protein, vegetables/fruit, whole grains, and omega-3-rich foods (fish, flax) to support general nerve/muscle health; stay hydrated; ensure vitamin D and B-complex at recommended amounts if you’re low. Avoid/limit: excess alcohol (can worsen neuropathy), smoking (vascular risk), megadoses of vitamin B6 (can cause neuropathy), and ultra-processed foods that worsen inflammation and weight. Discuss any supplement with your clinician, especially if you’re on multiple medicines. Mayo Clinic

---

Frequently asked questions

1) Is TFG-CMT2 different from other CMT?
Yes. It’s an axonal form (CMT2) linked to TFG gene changes. Many other CMT types affect myelin (CMT1). This difference changes what nerve tests look like but not day-to-day rehab goals. Orpha+1

2) How common is it?
Extremely rare—prevalence is estimated at fewer than 1 in a million for the TFG subtype. Orpha

3) What symptoms usually appear first?
Foot weakness, tripping, high arches, hammertoes, and reduced ankle reflexes—slowly progressive over years. Hand weakness may come later. Mayo Clinic

4) How is it confirmed?
Through exam, NCS/EMG showing axonal findings, and genetic testing identifying a TFG mutation. Medscape+1

5) Is there a cure?
Not yet. Current care is supportive—rehab, orthoses, and surgery if needed. Research is active. PMC

6) Will exercise make it worse?
Supervised exercise is beneficial, and studies do not show overwork damage when programs are well designed. PubMed+1

7) Which pain medicines work best?
SNRIs (duloxetine), alpha-2-delta ligands (pregabalin/gabapentin), and certain topicals have evidence in neuropathic pain; selection is individualized and off-label in CMT. FDA Access Data+2FDA Access Data+2

8) Are there drugs I must avoid?
Some chemotherapy agents (e.g., vincristine, taxanes) are high-risk for nerve injury—work with your specialists to evaluate risks. CMT Research Foundation

9) Do vitamins or supplements cure it?
No. Some supplements may help symptoms in other neuropathies, but none reverse CMT. Discuss with your clinician. PLOS+1

10) Can surgery fix the nerves?
Surgery realigns bones/tendons for better function and pain relief; it does not repair the nerve damage itself. PMC

11) Should I get genetic counseling?
Yes—because it’s autosomal dominant, there’s a 50% chance of passing it to children. Counseling explains testing and options. nhs.uk

12) Will I need a wheelchair?
Many people remain ambulatory with braces and therapy; needs vary by person and time. Early bracing often maintains mobility longer. PMC

13) How often should I follow up?
Typically once or twice a year with neuromuscular and rehab teams, sooner if symptoms change. Mayo Clinic

14) Are clinical trials available?
Trials come and go; a neuromuscular specialist or rare disease registry can help you find options. PMC

15) What’s the long-term outlook?
Progression is usually slow over decades. With proactive rehab, orthoses, and foot care, most people maintain good quality of life. Mayo Clinic

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 01, 2025.